Samuel J Wohlstadter

8498879, Jul 30, 2013

Nov 10, 2008

12/291529

Francis Michon - Bethesda MD, US
Samuel L. Moore - Sykesville MD, US
Samuel J. Wohlstadter - Madison VA, US
Charles Quentin Davis - Frederick MD, US
Glen Otero - Del Mar CA, US
Aaron Haleva - Oakhurst NJ, US

Wellstat Vaccines, LLC - Gaithersburg MD

G06Q 10/00

705 2, 705 3

A system and method for assessing the immunological status of one or more individuals in a patient population is presented. The method includes establishing a database comprising a plurality of records of information each representative of the immune status of an individual in the population, each of said records including (1) current information from one or more assays for the presence of a biochemical, and (2) individual specific information comprising one or more of said individual's medical history, said individual's doctors' observations and historical, demographic, lifestyle, and familial information relating to said individual. The method further includes processing the information in said database to find trends or patterns relating to the immune status of individuals in said patient population; and using the said trends or patterns as part of a health care related decision making process.

20060218010, Sep 28, 2006

Oct 18, 2005

11/255161

Francis Michon - Bethesda MD, US
Samuel Moore - Sykesville MD, US
Peter Fusco - Silver Spring MD, US
Samuel Wohlstadter - Madison VA, US
Charles Davis - Frederick MD, US
David Coleman - Gaithersburg MD, US
Suraj Shetty - Arlington VA, US
Kamini Joshi - Ashburn VA, US

BioVeris Corporation - Gaithersburg MD

G06F 19/00
G01N 33/48

705003000, 702019000

A system and method for obtaining, storing, processing and utilizing immunologic information of individuals and populations is presented. In exemplary embodiments of the present invention, a biological sample can be taken from one or more individuals and the sample submitted to one or more panels of assays. The results of the assays can be stored and analyzed, and such analysis can include (i) calculating derived quantities which take the results of the assays as inputs, and (ii) submitting the results and the derived quantities to a set of rules, each of which has a defined output state. In exemplary embodiments of the present invention, based upon the output state of the rules, an appropriate recommendation as to one or more immunization or other interventions can be generated and incorporated with provider and patient reminders. In exemplary embodiments of the present invention the results of the assays and the recommendation, as well as additional information specific to the individual can be stored for further analysis. In exemplary embodiments of the present invention the assay panel or panels can be chosen as a function of a defined demographic group or enterprise affinity into which the individual corresponds. In exemplary embodiments a database can be maintained for storing and further processing of all immunologic informatics collected according to the methods of the present invention, and can be further processed or used to optimize the delivery of products and/or services in various commercial, research and governmental contexts.

20080091471, Apr 17, 2008

Apr 27, 2007

11/796727

Francis Michon - Bethesda MD, US
Samuel Moore - Sykesville MD, US
Peter Fusco - Silver Spring MD, US
Samuel Wohlstadter - Madison VA, US
Charles Davis - Frederick MD, US
Aaron Haleva - Oakhurst NJ, US

BIOVERIS CORPORATION - Gaithersburg MD

G06Q 50/00
G06F 17/18

705003000

A system and method for assessing the immunological status of one or more individuals in a patient population is presented. The method includes establishing a database comprising a plurality of records of information each representative of the immune status of an individual in the population, each of said records including (1) current information from one or more assays for the presence of a biochemical, and (2) individual specific information comprising one or more of said individual's medical history, said individual's doctors' observations and historical, demographic, lifestyle, and familial information relating to said individual. The method further includes processing the information in said database to find trends or patterns relating to the immune status of individuals in said patient population; and using the said trends or patterns as part of a health care related decision making process. In exemplary embodiments of the present invention, processing the information in the database includes generating a list of correlations between variables or fields in the database, and for each correlation in the list generating a set of hypotheses that may explain said correlation. In exemplary embodiments of the present invention, as to each hypothesis in the set, automatically refuting, supporting or stating that there is insufficient data to analyze said hypothesis by further processing of the database; and reporting the correlations, their associated hypotheses and the refutation, support, or determination of insufficient data to refute or support, to a user.

20210301037, Sep 30, 2021

Mar 23, 2021

17/210124

- Rockville MD, US
Samuel J. WOHLSTADTER - Madison VA, US
Frank COMER - Gaithersburg MD, US
Kuishu REN - Columbia MD, US

C08B 37/08
A61K 47/64
A61K 39/00
A61K 39/385
C07K 16/14

A compound comprising one or more polysaccharide moieties each independently represented by the formula β(1→4)-[GlcNH—R]-2,5-anhydromannose, wherein n is a positive integer from 3 to 500, and R is H or an acyl group, is described. The compound can be manufactured by (a) reacting chitosan with an acylating agent sufficient to partially N-acylate the chitosan, yielding a modified chitin/chitosan mixed polymer; and (b) reacting the modified chitin/chitosan mixed polymer with a deaminating agent to cleave the mixed polymer at the unacylated chitosan moieties. The compound can be used to immunize against fungal infection. Antibodies specific to the compound, and the use of such antibodies to protect against fungal infection are also described.

20200339707, Oct 29, 2020

Jul 14, 2020

16/928545

- Rockville MD, US
Samuel J. WOHLSTADTER - Madison VA, US
Frank COMER - Gaithersburg MD, US
Kuishu REN - Columbia MD, US

C08B 37/08
A61K 47/64
A61K 39/00
A61K 39/385
C07K 16/14

A compound comprising one or more polysaccharide moieties each independently represented by the formula β(1→4)-[GlcNH—R]-2,5-anhydromannose, wherein n is a positive integer from 3 to 500, and R is H or an acyl group, is described. The compound can be manufactured by (a) reacting chitosan with an acylating agent sufficient to partially N-acylate the chitosan, yielding a modified chitin/chitosan mixed polymer; and (b) reacting the modified chitin/chitosan mixed polymer with a deaminating agent to cleave the mixed polymer at the unacylated chitosan moieties. The compound can be used to immunize against fungal infection. Antibodies specific to the compound, and the use of such antibodies to protect against fungal infection are also described.

20200062866, Feb 27, 2020

Oct 29, 2019

16/666503

- Rockville MD, US
Samuel J. WOHLSTADTER - Madison VA, US
Frank COMER - Gaithersburg MD, US
Kuishu REN - Columbia MD, US

C08B 37/08
C07K 16/14
A61K 39/385
A61K 39/00
A61K 47/64

A compound comprising one or more polysaccharide moieties each independently represented by the formula β(1→4)-[GlcNH—R]-2,5-anhydromannose, wherein n is a positive integer from 3 to 500, and R is H or an acyl group, is described. The compound can be manufactured by (a) reacting chitosan with an acylating agent sufficient to partially N-acylate the chitosan, yielding a modified chitin/chitosan mixed polymer; and (b) reacting the modified chitin/chitosan mixed polymer with a deaminating agent to cleave the mixed polymer at the unacylated chitosan moieties. The compound can be used to immunize against fungal infection. Antibodies specific to the compound, and the use of such antibodies to protect against fungal infection are also described.

20190169315, Jun 6, 2019

Feb 5, 2019

16/267430

- Rockville MD, US
Samuel J. WOHLSTADTER - Madison VA, US
Frank COMER - Gaithersburg MD, US
Kuishu REN - Columbia MD, US

C08B 37/08
A61K 47/64
A61K 39/00
C07K 16/14
A61K 39/385

A compound comprising one or more polysaccharide moieties each independently represented by the formula β(1→4)-[GlcNH-R]-2,5-anhydromannose, wherein n is a positive integer from 3 to 500, and R is H or an acyl group, is described. The compound can be manufactured by (a) reacting chitosan with an acylating agent sufficient to partially N-acylate the chitosan, yielding a modified chitin/chitosan mixed polymer; and (b) reacting the modified chitin/chitosan mixed polymer with a deaminating agent to cleave the mixed polymer at the unacylated chitosan moieties. The compound can be used to immunize against fungal infection. Antibodies specific to the compound, and the use of such antibodies to protect against fungal infection are also described.

20180251573, Sep 6, 2018

May 1, 2017

15/583396

- Rockville MD, US
Samuel J. WOHLSTADTER - Madison VA, US
Frank COMER - Gaithersburg MD, US
Kuishu REN - Columbia MD, US

C08B 37/08
C07K 16/14

A compound comprising one or more polysaccharide moieties each independently represented by the formula β(1→4)-[GlcNH-R]-2,5-anhydromannose, wherein n is a positive integer from 3 to 500, and R is H or an acyl group, is described. The compound can be manufactured by (a) reacting chitosan with an acylating agent sufficient to partially N-acylate the chitosan, yielding a modified chitin/chitosan mixed polymer; and (b) reacting the modified chitin/chitosan mixed polymer with a deaminating agent to cleave the mixed polymer at the unacylated chitosan moieties. The compound can be used to immunize against fungal infection. Antibodies specific to the compound, and the use of such antibodies to protect against fungal infection are also described.